< Back to search
Filter
1

Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer

for
Ovarian Cancer
Location: Manchester NH, Lebanon NH
Sponsor: Tyler J Curiel

Sex: Female

Age: 18+

Code: NCT06815497

Phase2, Recruiting

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

for
Epithelial Ovarian Cancer
Location: Burlington MA, Towson MD, Washington D.C. DC,
Sponsor: AstraZeneca

Sex: Female

Age: 18+

Code: NCT07218809

Phase3, Recruiting

A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

for
Ovarian Cancer
Location: Boston MA, Worcester MA, New York NY, Hackensack NJ,
Sponsor: Incyte Corporation

Sex: Female

Age: 18 - 70+

Code: NCT07023627

Phase2, Recruiting

Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer

for
Endometrioid Ovarian Cancer, Primary Peritoneal Cancer,
Location: Aurora CO
Sponsor: University of Colorado, Denver

Sex: Female

Age: 18+

Code: NCT06856499

Phase1, Recruiting

DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer

for
Ovarian Cancer, Ovarian Carcinoma, Recurrent Ovary Cancer,
Location: Boston MA
Sponsor: Elizabeth Stover, MD, PhD

Sex: Female

Age: 18+

Code: NCT06964009

Phase1, Recruiting

Interested in new platinum-resistant ovarian cancer trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

for
Ovarian Cancer, Fallopian Tube Cancer,
Location: Boston MA, Quebec, Greenfield Park, Montreal, Miami FL,
Sponsor: Regeneron Pharmaceuticals

Sex: Female

Age: 18+

Code: NCT06787612

Phase2, Recruiting

Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer

for
Ovarian Cancer
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: Female

Age: 18+

Code: NCT05636111

Phase1, Recruiting

Oral Minoxidil for the Treatment of Recurrent Platinum Resistant Epithelial Ovarian Cancer

for
Ovarian Cancer
Location: Maywood IL
Sponsor: Loyola University

Sex: Female

Age: 18 - 70+

Code: NCT05272462

Phase2, Recruiting

Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer

for
Ovarian Cancer
Location: Chicago IL
Sponsor: Canadian Cancer Trials Group

Sex: Female

Age: 18+

Code: NCT04918186

Phase2, Recruiting

Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer

for
Ovarian Cancer, Endometrial Cancer
Location: Baltimore MD
Sponsor: Sinai Hospital of Baltimore

Sex: Female

Age: 18 - 70+

Code: NCT02188550

Phase2, Recruiting

Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

for
Platinum-Resistant Fallopian Tube Carcinoma,
Location: Pittsburgh PA
Sponsor: Ronald Buckanovich

Sex: Female

Age: 18+

Code: NCT05538091

Phase2, Recruiting

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

for
Recurrent Endometrial Carcinoma,
Location: Providence RI, Philadelphia PA, Cleveland OH,
Sponsor: National Cancer Institute (NCI)

Sex: Female

Age: 18+

Code: NCT05950464

Phase1, Recruiting

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

for
Ovarian Clear Cell Adenocarcinoma,
Location: Buffalo NY, Houston TX
Sponsor: Roswell Park Cancer Institute

Sex: Female

Age: 18+

Code: NCT05231122

Phase2, Recruiting

Clinical Trial of Autologous B7-H3 CAR T Cells in Reoccurent Platinum-resistant Ovarian Tumors

for
Ovarian Cancer
Location: Palo Alto CA
Sponsor: Stanford University

Sex: Female

Age: 18+

Code: NCT06646627

Phase1, Recruiting

A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

for
Ovarian Cancer
Location: Beverly Hills CA, Torrance CA
Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

Sex: Female

Age: 18+

Code: NCT07546500

Phase3, Recruiting

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

for
Ovarian Neoplasms, Fallopian Tube Neoplasms,
Location: Scarborough ME, Providence RI, Farmington CT,
Sponsor: Eli Lilly and Company

Sex: All

Age: 18+

Code: NCT07213804

Phase3, Recruiting

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

for
Solid Cancer
Location: New Haven CT, Lake Success NY, New York NY, Teaneck NJ,
Sponsor: Daiichi Sankyo

Sex: All

Age: 18+

Code: NCT06161025

Phase2, Phase3, Recruiting

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

for
Head and Neck Squamous Cell Carcinoma (HNSCC),
Location: New York NY, Columbus OH, Grand Rapids MI,
Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

Sex: All

Age: 18+

Code: NCT05985655

Phase1, Phase2, Recruiting

A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

for
High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer,
Location: Boston MA, Burlington MA, Hartford CT, Springfield MA,
Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

Sex: Female

Age: 18+

Code: NCT05128825

Phase2, Recruiting
Featured

A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine

for
Advanced High-Grade Epithelial Ovarian Cancer,
Location: Worcester MA, Pittsburgh PA, Sarasota FL, Detroit MI,
Sponsor: AbbVie

Sex: Female

Age: 18+

Code: NCT06682988

Phase2, Recruiting